- Home
- PIPR vs RARE Comparison
PIPR vs RARE Comparison
Compare PIPR & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIPR
- RARE
- Stock Information
- Founded
- PIPR 1895
- RARE 2010
- Country
- PIPR United States
- RARE United States
- Employees
- PIPR N/A
- RARE N/A
- Industry
- PIPR Investment Bankers/Brokers/Service
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- PIPR Finance
- RARE Health Care
- Exchange
- PIPR Nasdaq
- RARE Nasdaq
- Market Cap
- PIPR 4.1B
- RARE 3.3B
- IPO Year
- PIPR N/A
- RARE 2014
- Fundamental
- Price
- PIPR $254.68
- RARE $37.14
- Analyst Decision
- PIPR Hold
- RARE Strong Buy
- Analyst Count
- PIPR 3
- RARE 15
- Target Price
- PIPR $286.00
- RARE $90.53
- AVG Volume (30 Days)
- PIPR 113.6K
- RARE 1.1M
- Earning Date
- PIPR 08-01-2025
- RARE 07-31-2025
- Dividend Yield
- PIPR 2.19%
- RARE N/A
- EPS Growth
- PIPR 93.72
- RARE N/A
- EPS
- PIPR 11.46
- RARE N/A
- Revenue
- PIPR $1,540,130,000.00
- RARE $590,689,000.00
- Revenue This Year
- PIPR $8.46
- RARE $18.94
- Revenue Next Year
- PIPR $17.89
- RARE $28.93
- P/E Ratio
- PIPR $22.21
- RARE N/A
- Revenue Growth
- PIPR 10.55
- RARE 33.46
- 52 Week Low
- PIPR $202.91
- RARE $29.59
- 52 Week High
- PIPR $351.80
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- PIPR 49.50
- RARE 52.29
- Support Level
- PIPR $252.02
- RARE $36.01
- Resistance Level
- PIPR $257.66
- RARE $40.19
- Average True Range (ATR)
- PIPR 4.97
- RARE 1.47
- MACD
- PIPR -0.88
- RARE 0.06
- Stochastic Oscillator
- PIPR 34.82
- RARE 49.92
About PIPR Piper Sandler Companies
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.